For a company committed to transparency of disclosure, Pfizer’s plans for disseminating its Covid-19 vaccine updates have been pretty opaque. Sellside analysts spent 1.5 hours dragging information out of chief executive Albert Bourla today – a clear statement of intent would have made the situation a lot simpler.
This intense scrutiny is entire of Pfizer’s making, of course; the company had long talked up an October interim readout, and when an update failed to materialize alongside third-quarter results today Mr. Bourla was forced to explain when the news might come. The answer was November. Probably.